A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2009
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Pfizer
- 28 Sep 2008 Planned end date changed from 1 Jul 2008 to 1 Mar 2008 as reported by CT.gov
- 28 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
- 24 Aug 2008 Actual patient number (392) added as reported by ClinicalTrials.gov.